Add this topic to your myFT Digest for news straight to your inbox
The UK’s poor progress has less to do with its flaws than with US strengths, writes Geoffrey Owen
Drugmakers unsettled as large tech groups turn to healthcare
Hiring of Scheller, formerly of Genentech, a sign of drive to shake up world of drug development
Japanese drugmaker denies any talks with Swiss group
Chief has kept to script over drug developing
Big pharma faces new challenges, says Andrew Jack
The best chance of preventing the disease lies in blocking the formation of both bap and tau
Roche CFO led process to finance $40bn buyout of rival
Roche has seen off poison pill defences before without the price rising too much
The former Daewoo Motor executive is making waves in the drug industry, writes Song Jung-a
Kevin Lilley of Old Mutual picks out investment themes for the eurozone
New chief executive has huge shoes to fill as he manages the change to slower growth
International Edition